Skip to main content

Table 3 Comparison of anti-osteoporotic medication treatment initiated after hip fracture and mortality risk

From: Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study

Study
[Ref. no.]
Country Design of included studies No. of patients Study population Follow-up durations, means (Y) AOM choice Within Time to AOM Mortality risk (95% CI)
Cree et al.
(2003) [16]
Canada Prospective,
Observational
81 (treated)
275 (non-treated)
F and M
Age ≥ 65
4Y HRT, BO, calcitonin, vit-D3 Post-fx 6 M (37%) 0.25 (0.06–1.12) 1-year.
0.34 (0.17–0.70) long-term.
Lyles et al.
(2007) [17]
International, multicenter RCT 1065 (treated)
1062 (placebo)
F and M
Age ≥ 50
1.9 Y Zoledronic acid Post-op 90D 0.72
(0.56–0.93)
Cecilia et al.
(2009) [18]
Spain RCT 119 (treated)
120 (placebo)
F and M
Age ≥ 60
1Y Alendronate Post-op 2-4D 0.86 (.29–1.89)
Nurmi et al.
(2009) [19]
Finland Prospective,
Observational
103 (treated)
118 (non-treated)
F and M
Age ≥ 70 (80.5%)
4Y HRT, BO, vit-D3, calcitonin, SERM, teriparatide NA 0.8–0.98
Cameron et al.
(2010) [20]
Australia Nested case-control 83 (treated)
366 (non-treated)
F and M
Age ≥ 65
5 Y BO, HRT, vit-D3, calcitonin NA 0.20 (0.07–0.55) BO use in the first 3 years
Non-BO use: unremarkable
Beaupre et al.
(2011) [21]
Canada Prospective, Observational 101 (treated)
108 (non-treated)
F and M
Age ≥ 50
3Y Alendronate (68%), Risedronate (21%), Etidronate (11%). Post-fx 1Y (97%),
Post-fx 1-2Y (2%),
Post-fx 3Y (1%)
0.37 (0.28–0.51) per Year
0.92 (0.88–0.97) per Month
Osaki et al.
(2012) [22]
Japan Prospective
Observational
184 (treated)
445 (non-treated)
F
Age ≥ 70 (93.6%)
3Y Risedronate At the time of discharge from hospital 0.29 (0.04–2.37)
Bondo et al.
(2013) [23]
Danish Retrospective, Observational 1086 (treated)
2147 (non-treated)
F and M
Age ≥ 55
3.8Y BO Post-fx 4 M 0.76 (0.68–0.85)
Brozek et al.
(2016) [24]
Austrian Retrospective, Observational 2166 (treated)
4332 (non-treated)
F and M
Age ≥ 50
4Y BO Post-fx 1Y 0.24 (0.15–0.40) 90-days
0.43 (0.36–0.52) 1-year
0.48 (0.42–0.55) 3-year
Cengiz et al.
(2016) [25]
Turkey RCT 56 (treated)
58 (placebo)
F and M
Age ≥ 65
1Y Zolendronic acid Post-op 2 W 0.41 (0.20–0.86)
Current study
(2019)
Taiwan Retrospective, Observational 2092 (treated)
2092 (non-treated)
F and M
Age ≥ 65
5Y BO, raloxifene, calcitonin, teriparatide Post-fx 6 M 0.63 (0.58–0.68) Treated
0.42 (0.31–0.52) Adherence
0.84 (0.75–0.93) Non-adherence
  1. Post-op post-operative; Post-fx post-fracture; Y year; D day; M month; W week BO Bisphosphonate; RCT randomized control trial; AOM anti-osteoporotic medication; CI confidence interval; NA not available